TG Therapeutics
Business Services · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3020 Carrington Mill Blvd Ste 475, Morri...Phone Number
(212) 554-4484Website
www.tgtherapeutics.comRevenue
$700.3 MillionStock Symbol
TGTXIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
3
3
1
1
2
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York.Explore more
TG Therapeutics Org Chart
SC
Senior Director (Analytics & Insights)
IH
Senior Director, Marketing
KS
Regional Director, Marketing
AH
Regional Marketing Director - East
MV
Director, Patient Marketing
LF
Regional Director, Marketing Team
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TG Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
TG Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once TG Therapeutics has new funding data
Click to see if TG Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TG Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on TG Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at TG Therapeutics
Product Launch: Get notified when TG Therapeutics launches new products
Check if TG Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined TG Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to TG Therapeutics
Compare insights from companies similar to TG Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TG Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TG Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TG Therapeutics.
TG Therapeutics financials insights
Gather financial insights about TG Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$140M
TG Therapeutics Tech Stack
A closer look at the technologies used by TG Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
TG Therapeutics has reported a modeled AUC ratio of 1.21 (lower bound: 1.15) for its subcutaneous Brionvi formulation, well above the regulatory non-inferiority threshold of 0.8, with management characterizing the probability of falling below the threshold as a greater than 99th percentile tail-risk event.
Pharmaceuticals
Project
TG Therapeutics has reported an observed bioavailability of approximately 60% for its subcutaneous Brionvi formulation, with a selected dose of 1,200 mg subcutaneous providing an effective exposure of approximately 720 mg, above the 600 mg intravenous target equivalent.
Pharmaceuticals
Hiring Plans
TG Therapeutics has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Open Position
TG Therapeutics News & Media
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patientsIs TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?
Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on TGTX. TG Therapeutics, Inc.’s share was trading at $50.54 as of June 16th. TGTX’s trailing and forward P/E were 17.59 and 38.76 respectively according to Yahoo Finance. […]TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
TG Therapeutics, Inc. (TGTX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 2:00 PM EDTCompany ParticipantsMichael Weiss -...TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding TG Therapeutics
Sign Up For FreeTo access detailed company insights
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York.... Read More
